Tizanidine Tablet
Product Images NDC 70771-1335

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 70771-1335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Be5259c0 Aab1 4703 853c 453a7e8041c4 01)

Chemical structure of tizanidine hydrochloride, showing the arrangement of atoms including chlorine (Cl), nitrogen (N), sulfur (S), and hydrogen (H) within the molecule.*

FDA Label Image

Figure (Be5259c0 Aab1 4703 853c 453a7e8041c4 02)

A line graph showing plasma tizanidine concentration (ng/mL) over 24 hours after dosing with 2 x 4 mg tizanidine tablets or capsules. The graph compares four conditions: tablets with food, tablets without food, capsules with food, and capsules without food. Concentration peaks around 1-2 hours, then declines steadily in all conditions.*

FDA Label Image

Figure (Be5259c0 Aab1 4703 853c 453a7e8041c4 03)

A line graph depicting improvement in Ashworth Score over time (hours post-dose) for tizanidine 16 mg, 8 mg, and placebo. The Y-axis shows improvement, while the X-axis shows hours post-dose from 0 to 6. The 16 mg dose shows the greatest improvement, peaking around 2 hours, followed by 8 mg and placebo with smaller improvements.*

FDA Label Image

Figure (Be5259c0 Aab1 4703 853c 453a7e8041c4 04)

A line chart showing the improvement in Ashworth Score over time, comparing tizanidine (mean dose 28.8 mg) and placebo groups at three study points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph displays mean values with error bars for each group.*

FDA Label Image

Figure (Be5259c0 Aab1 4703 853c 453a7e8041c4 05)

Label of Tizanidine Tablets, USP 2 mg by Zydus Lifesciences Limited showing 150 tablets in the package. It states the active ingredient is tizanidine hydrochloride equivalent to 2 mg base per tablet, includes a warning that tizanidine tablets are not interchangeable with capsules, and provides storage instructions and manufacturer details (Cadila Healthcare Ltd., India).*

FDA Label Image

Figure (Be5259c0 Aab1 4703 853c 453a7e8041c4 06)

Label for tizanidine tablets USP 4 mg by Zydus Lifesciences Limited, containing 150 tablets. The label includes a warning that tizanidine tablets are not interchangeable with tizanidine capsules. It provides storage instructions and notes that each tablet contains 4 mg tizanidine base. The labeler is Cadila Healthcare Ltd., Ahmedabad, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.